Partner Maarika Kimbrell is quoted in Bloomberg Law discussing potential challenges to US Food and Drug Administration (FDA) rules and policies in a post-Chevron environment. Maarika told Bloomberg Law that companies with specific issues with FDA regulations and policies will have an easier time bringing challenges and succeed in those challenges.
“The landscape will be less certain, but that uncertainty is something that individual companies can and likely will take advantage of if the initial policies put out by FDA are things that are unfavorable to their company or otherwise object to,” she said.
Read the full Bloomberg Law article >>
Subscription may be required.